173 related articles for article (PubMed ID: 35923718)
1. Novel etodolac derivatives as eukaryotic elongation factor 2 kinase (eEF2K) inhibitors for targeted cancer therapy.
Comert Onder F; Siyah P; Durdagi S; Ay M; Ozpolat B
RSC Med Chem; 2022 Jul; 13(7):840-849. PubMed ID: 35923718
[TBL] [Abstract][Full Text] [Related]
2. Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies.
Onder FC; Durdagi S; Kahraman N; Uslu TN; Kandemir H; Atici EB; Ozpolat B; Ay M
Bioorg Chem; 2021 Nov; 116():105296. PubMed ID: 34488125
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of eEF2K synergizes with glutaminase inhibitors or 4EBP1 depletion to suppress growth of triple-negative breast cancer cells.
Ju Y; Ben-David Y; Rotin D; Zacksenhaus E
Sci Rep; 2021 Apr; 11(1):9181. PubMed ID: 33911160
[TBL] [Abstract][Full Text] [Related]
6. In silico, synthesis and anticancer evaluation of benzamide tryptamine derivatives as novel eEF2K inhibitors.
Liu Z; Jiang A; Wang Y; Xu P; Zhang Q; Wang Y; He S; Wang N; Jin H; Zhang B
Bioorg Med Chem Lett; 2022 Jul; 67():128759. PubMed ID: 35483594
[TBL] [Abstract][Full Text] [Related]
7. Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.
Karakas D; Ozpolat B
J Mol Med (Berl); 2020 Jun; 98(6):775-787. PubMed ID: 32377852
[TBL] [Abstract][Full Text] [Related]
8. Design and Characterization of a Novel eEF2K Degrader with Potent Therapeutic Efficacy Against Triple-Negative Breast Cancer.
Zhong C; Zhu R; Jiang T; Tian S; Zhao X; Wan X; Jiang S; Chen Z; Gong R; He L; Yang JM; Ye N; Cheng Y
Adv Sci (Weinh); 2024 Feb; 11(5):e2305035. PubMed ID: 38084501
[TBL] [Abstract][Full Text] [Related]
9. eEF2 kinase mediated autophagy as a potential therapeutic target for paclitaxel-resistant triple-negative breast cancer.
Wang RX; Xu XE; Huang L; Chen S; Shao ZM
Ann Transl Med; 2019 Dec; 7(23):783. PubMed ID: 32042799
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer.
Guo Y; Zhao Y; Wang G; Chen Y; Jiang Y; Ouyang L; Liu B
Eur J Med Chem; 2018 Jan; 143():402-418. PubMed ID: 29202403
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G
Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948
[TBL] [Abstract][Full Text] [Related]
12. Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases.
Liu R; Proud CG
Acta Pharmacol Sin; 2016 Mar; 37(3):285-94. PubMed ID: 26806303
[TBL] [Abstract][Full Text] [Related]
13. Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.
Bayraktar R; Ivan C; Bayraktar E; Kanlikilicer P; Kabil NN; Kahraman N; Mokhlis HA; Karakas D; Rodriguez-Aguayo C; Arslan A; Sheng J; Wong S; Lopez-Berestein G; Calin GA; Ozpolat B
Clin Cancer Res; 2018 Sep; 24(17):4225-4241. PubMed ID: 29748184
[No Abstract] [Full Text] [Related]
14. Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy.
Zhang B; Zou J; Zhang Q; Wang Z; Wang N; He S; Zhao Y; Naman CB
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673713
[TBL] [Abstract][Full Text] [Related]
15. Discovery of New Inhibitors of eEF2K from Traditional Chinese Medicine Based on In Silico Screening and In Vitro Experimental Validation.
Fu Q; Liu X; Li Y; Wang P; Wu T; Xiao H; Zhao Y; Liao Q; Song Z
Molecules; 2022 Jul; 27(15):. PubMed ID: 35956836
[TBL] [Abstract][Full Text] [Related]
16. Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells.
Xie CM; Liu XY; Sham KW; Lai JM; Cheng CH
Autophagy; 2014 Sep; 10(9):1495-508. PubMed ID: 24955726
[TBL] [Abstract][Full Text] [Related]
17. Integrative bioinformatics and proteomics-based discovery of an eEF2K inhibitor (cefatrizine) with ER stress modulation in breast cancer cells.
Yao Z; Li J; Liu Z; Zheng L; Fan N; Zhang Y; Jia N; Lv J; Liu N; Zhu X; Du J; Lv C; Xie F; Liu Y; Wang X; Fei Z; Gao C
Mol Biosyst; 2016 Mar; 12(3):729-36. PubMed ID: 26776155
[TBL] [Abstract][Full Text] [Related]
18. Eukaryotic Elongation Factor 2 Kinase a Pharmacological Target to Regulate Protein Translation Dysfunction in Neurological Diseases.
Beretta S; Gritti L; Verpelli C; Sala C
Neuroscience; 2020 Oct; 445():42-49. PubMed ID: 32088293
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting Eukaryotic Elongation Factor 2 Kinase: An Update on Pharmacological Small-Molecule Compounds in Cancer.
Zhu S; Liao M; Tan H; Zhu L; Chen Y; He G; Liu B
J Med Chem; 2021 Jul; 64(13):8870-8883. PubMed ID: 34162208
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions.
Yoshimori A; Kawasaki E; Murakami R; Kanai C
Medicines (Basel); 2021 May; 8(5):. PubMed ID: 34065377
[No Abstract] [Full Text] [Related]
[Next] [New Search]
